Dr Agarwal's Healthcare IPO GMP slips on Day 2; subscription drags at 8%

Q: How long will it take to read this news story?

The story "Dr Agarwal&#039;s Healthcare IPO GMP slips on Day 2; subscription drags at 8%" has 574 words across 23 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Dr Agarwal&#039;s Healthcare IPO GMP slips on Day 2; subscription drags at 8%" was covered 1 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 300 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #25618837</li><li>URL: https://chronographically.beamstart.com/news/dr-agarwals-healthcare-ipo-gmp-17382131068399</li></ul>

Business Standard Logo Business Standard 1d ago

Dr Agarwal's Healthcare IPO GMP slips on Day 2; subscription drags at 8% - Business Standard

Quick Summary:

The unlisted shares of Dr Agarwal's Healthcare were trading at around Rs 407 apiece, reflecting a grey market premium (GMP) of Rs 5 or 1.

Dr Agarwal's Health Care provides a wide range of eye care services, including cataract surgery, refractive surgery, and other surgical procedures.

The public offering has received bids for 42,53,130 shares against the 5,35,26,172 shares offered, translating to a subscription of just 0.08 times till around 10:04 AM on Janauray 30. NSE data shows that Retail Individual Investors (RIIs) have subscribed 0.13 times, while Non-Institutional Investors (NIIs) have subscribed 0.06 times.